Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium selenate for behavioural variant frontotemporal dementia
ACTRN12620000236998Phase 2Recruiting
- Sponsor
- Alfred Health
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in behavioral variant frontotemporal dementia (bvFTD) and progressive non-fluent aphasia (PNFA) comparing Sodium selenate with Placebo (2 arms). Primary endpoint: Change in global brain volume. Started Aug 2021; status: recruiting.
02
Drugs
sodium selenate
03
Conditions
behavioral variant frontotemporal dementia (bvFTD)progressive non-fluent aphasia (PNFA)
Beyond the preview
Go deeper on ACTRN12620000236998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000236998.